Effects of glucocorticoids on osteoclast-activating factor

Area of Science:

• Endocrinology
• Oncology
• Bone Biology

Background:

• Hypercalcemia is a common complication in patients with multiple myeloma and lymphoproliferative disorders.
• Osteoclast-activating factor (OAF) is a lymphokine implicated in the bone lesions and hypercalcemia associated with these hematological neoplasms.
• Glucocorticoids are known to lower serum calcium levels in these patients, but the precise mechanism remains unclear.

Purpose of the Study:

• To investigate the effects of cortisol on the production and biological activity of OAF.
• To elucidate the mechanism by which glucocorticoids exert their calcium-lowering effects in patients with hematological neoplasms.

Main Methods:

• In vitro assessment of OAF's effect on bone resorption.
• Exposure of OAF-containing media to varying concentrations of cortisol (10-5M to 10-9M).
• Evaluation of cortisol's impact on OAF production by cells.

Main Results:

• Cortisol significantly inhibited the bone-resorbing effects of OAF at concentrations ranging from 10-5M to 10-9M.
• Cortisol did not inhibit OAF production at concentrations below 10-5M.
• These findings suggest a direct effect of glucocorticoids on bone resorption.

Conclusions:

• Glucocorticoids primarily lower serum calcium in myeloma and related disorders by directly inhibiting bone resorption.
• The therapeutic action of glucocorticoids is likely mediated by counteracting the effects of OAF on bone, rather than suppressing OAF production.
• This study supports a direct mechanism of action for glucocorticoids on osteoclasts or bone cells.